# Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

> **NCT05407987** · PHASE3 · RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 82 (estimated)

## Conditions studied

- Gynecologic Cancer
- Anemia
- Iron-deficiency

## Interventions

- **DRUG:** Ferric derisomaltose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05407987
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407987, "Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05407987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*